EyePoint, Inc. shares its financial situation and plans to cut its workforce by about 53%.

Oct 19, 2026, 9:27 AM ETTroubleRead the original at SEC EDGAR

Bad for EYPT

EyePoint will end its pivotal wet AMD trials early and cut about 53% of its staff. Those losses outweigh the benefit of focusing more resources on its DME program.

EYPT · EyePoint, Inc.

AI read · Bad for EYPT

The AI's read

EyePoint’s remaining late-stage work is focused on DME, which may help it concentrate spending. The filing does not say what LUCIA’s results showed. Still, ending the wet AMD trials and cutting about 53% of staff outweighs that focus, especially with about $9 million in expected cash costs.

Get alerts for EYPT

Follow EyePoint, Inc. (EYPT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for EYPT

Free on the App Store and Google Play, or on the web.